Free Daily Podcast Summary
The BioCentury Show: Daily Summaries Delivered
by BioCentury
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago37 min
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs. As Pops prepares to retire as CEO (he will remain chairman), he spoke with B...
- 3 weeks ago36 min
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing r...
- May 1, 202633 min
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood. Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s appro...
- Apr 17, 202637 min
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally. “We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in...
- Apr 3, 202633 min
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving. Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simo...
- Mar 20, 202639 min
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration. View full story: https://www.biocentury.com/article/658829 ...
- Mar 6, 202635 min
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show. In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s inv...
- Feb 18, 202640 min
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
Caution: This episode of The BioCentury Show contains strong language. In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S. In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation R...
About The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The BioCentury Show in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The BioCentury Show daily summary?
It's a free AI-powered email that summarizes new episodes of The BioCentury Show as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The BioCentury Show podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The BioCentury Show product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioCentury.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The BioCentury Show release new episodes?
The BioCentury Show publishes biweekly. Our AI generates a summary within hours of each new episode.
What topics does The BioCentury Show cover?
The BioCentury Show covers topics including Science, Business, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The BioCentury Show summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.